ONE STAGE CHRONOMETRIC FVIII ASSAY OR TWO STAGE CHROMOGENIC FVIII ASSAY TO DIAGNOSE HAEMOPHILIA A?

被引：0
|
作者：
Marchand, K. [1 ]
Benoit, R. [1 ]
Martin, M. [2 ]
Fretigny, M. [3 ]
Toussaint-Hacquard, M. [1 ]
Frotscher, B. [2 ]
机构：
[1] Univ Hosp Nancy, Lab Haematol, Vandoeuvre Les Nancy, France
[2] Univ Hosp Nancy, Haemophilia Treatment Ctr, Vandoeuvre Les Nancy, France
[3] Univ Hosp Lyon, Lab Genet, Lyon, France
来源：
HAEMOPHILIA | 2022年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO012
引用
收藏
页码：30 / 30
页数：1
相关论文
共 50 条
  • [41] Comparison of a ELISA FVIII inhibitor assay with the Nijmegen Modified Bethesda assay in patients with inherited and acquired haemophilia A
    Riddell, A.
    Pickering, W. M.
    Lawler, P.
    Yildiz, L.
    Drebes, A.
    Yee, T.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 935 - 935
  • [42] Evaluation of one-stage and chromogenic assays for the measurement of FVIII:C post valoctocogene roxaparvovec infusion
    Platton, S.
    Raheja, P.
    Dale, C.
    Guy, S.
    Yartey, N.
    Bowyer, A.
    HAEMOPHILIA, 2024, 30 : 44 - 45
  • [43] THE SPECIFICITY OF THE ASSAY DETERMINES THE MEASUREMENT OF FVIII ANTIGEN LEVELS IN PATIENTS WITH SEVERE HAEMOPHILIA A
    Lavend'homme, R.
    Van Laer, C.
    Vandenbriele, C.
    Hermans, C.
    Lambert, C.
    Van Dievoet, M. A.
    Peerlinck, K.
    Jacquemin, M.
    HAEMATOLOGICA, 2021, 106 (09) : 9 - 9
  • [44] Measuring FVIII activity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clotting and chromogenic assay kits: a two-centre study
    Hillarp, A.
    Bowyer, A.
    Ezban, M.
    Persson, P.
    Kitchen, S.
    HAEMOPHILIA, 2017, 23 (03) : 458 - 465
  • [45] The activity of glycoPEGylated recombinant FVIII (N8-GP) can be measured in both two-stage chromogenic and one-stage clotting assays
    Krogh-Meibom, T.
    Olsen, E. H. N.
    Kjalke, M.
    Ezban, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 1042 - 1042
  • [46] In vitro validation of chromogenic substrate assay for evaluation of surrogate FVIII-activity of emicizumab
    Yamaguchi, Tomoko
    Shinozawa, Keiko
    Nagatoishi, Satoru
    Mitsuhashi, Ayano
    Bingo, Masato
    Inaba, Hiroshi
    Amano, Kagehiro
    Tsumoto, Kohei
    Kinai, Ei
    THROMBOSIS RESEARCH, 2023, 222 : 131 - 139
  • [47] Haemophilia a patients with discordant FVIII levels by 1-stage & chromogenic assays show reduced thrombin generation & increased bleeding
    Khoo, L. T.
    Kershaw, G. W.
    Curnow, J.
    Morel-Kopp, M.
    Matthews, S.
    Waite, C.
    Dunkley, S.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 811 - 812
  • [48] RivaroxabanAbnormal levels of FVIII clotting assay
    Reactions Weekly, 2024, 2007 (1) : 301 - 301
  • [49] The thrombin generation assay as a method for monitoring haemophilia A patients using emicizumab and FVIII treatment
    Monard, A.
    Urlings, E.
    van de Berg, T.
    Hellenbrand, D.
    van Oerle, R.
    Beckers, E.
    Heubel-Moenen, F.
    Henskens, Y.
    HAEMOPHILIA, 2024, 30 : 41 - 41
  • [50] EFFECTS OF PREANALYTICAL CONDITIONS ON FVIII ASSAY IN HEALTHY DONORS AND FVIII DEFICIENCY STATES
    Vatansever, Pinar
    Turkal, Rana
    Cevlik, Tulay
    Sirikci, Onder
    Haklar, Goncagul
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2018, 40 : 150 - 150
12345